Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H27FN2O |
Molecular Weight | 354.461 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=C(F)C=C3
InChI
InChIKey=KXUBAVLIJFTASZ-UHFFFAOYSA-N
InChI=1S/C22H27FN2O/c1-2-22(26)25(20-10-8-19(23)9-11-20)21-13-16-24(17-14-21)15-12-18-6-4-3-5-7-18/h3-11,21H,2,12-17H2,1H3
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10945855 |
4.2 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2907025 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
On a black market, parafluorofentanyl is distributed in form of capsules and tablets containing the drug in the range of 33.8-408.7 ug. In preclinical studies parafluorofentanyl was administered to rats subcutaneously.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10945855
The potency of parafluorofentanyl with respect to cloned hMOR was investigated using the heterologous expression in X. laevis. Receptor subtype was individually coexpressed with GIRK1/GIRK2 channels and RGS4, mimicking the native neuronal G protein-mediated pathway of K1 channel activation. The two-microelectrode voltage-clamp technique was then used to measure the opioid receptor-activated GIRK1/GIRK2 channel response as the increase of the inward K1 current at 270 mV, evoked by the application of increasing concentrations of opioid ligands. Parafluorofentanyl activated hMOR with EC50 of 4.2 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-4-Fluorofentanyl
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
||
|
DEA NO. |
9812
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
||
|
WIKIPEDIA |
List_of_fentanyl_analogues
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
||
|
YELLOW LIST |
NF 003
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB09177
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | |||
|
90736-23-5
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | |||
|
I45R05QM0Z
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | |||
|
62300
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | |||
|
300000013173
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | |||
|
DTXSID0048929
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | |||
|
4-FLUOROFENTANYL
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | |||
|
Parafluorofentanyl
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY | Parafluorofentanyl (4-Fluorofentanyl) is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. | ||
|
61074
Created by
admin on Fri Dec 15 19:38:46 GMT 2023 , Edited by admin on Fri Dec 15 19:38:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE INACTIVE)
SALT/SOLVATE (PARENT)